• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA to set up technical group in the context of the publication of clinical data

EMA to set up technical group in the context of the publication of clinical data

March 24, 2017
CenterWatch Staff

The EMA has launched a call for applications to join a technical anonymization group (TAG) that will help the Agency to further develop best practices for the anonymization of clinical reports. The goal is to set up a multidisciplinary team with a broad range of expertise.

As of October 2016, the EMA gives open access to clinical reports on medicines under phase I of its policy on the publication of clinical data (EMA Policy 0070). This requires the anonymization of reports in line with European personal data protection law.

Anonymization of clinical reports poses a major challenge to those directly involved (pharmaceutical industry, clinical research organizations and EMA) and to those accessing the data (patients, healthcare professionals and academia). The Agency has already published comprehensive guidance on the anonymization of the reports. However, as data anonymization is a rapidly evolving field, EMA wants to keep abreast of developments and continue to update the guidance with the support of experts.

The proposed technical group will consider the experience gained with the publication of clinical reports from the first phase of the implementation of EMA’s publication of clinical data policy. It will assess best anonymization practices, and any risks to privacy and re-identification of patients in the light of new technological developments. In addition, it will investigate how the anonymization methodology used impacts the scientific utility of the published data, and establish whether secondary analysis of the data can be successfully undertaken.

To address these challenges, the group will be composed of data protection experts, experts in re-analysis of clinical data from academia, industry professionals with direct experience in the anonymization of clinical data, professionals developing de-identification standards and guidance, and representatives of patient and healthcare professional organizations.

Individuals interested in becoming members of the TAG can consult the group’s terms of reference in annex to the call for applications, and should send their CV and the declaration of interests form to tag@ema.europa.eu by 28 April 2017.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing